Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Charles River Laboratories and Atomwise Form a Strategic Alliance to Provide Integrated, Artificial Intelligence-Driven Drug Discovery

By Charles River Laboratories International | January 14, 2019

Charles River Laboratories International, Inc. (NYSE: CRL) and Atomwise, Inc. today announced the formation of a strategic alliance that offers clients access to Atomwise’s artificial intelligence (AI)-powered, structure-based, drug design technology, which allows scientists to predict how well a small molecule will bind to a target protein of interest. By removing sole reliance on empirical screening, AI enables drug researchers to test an extremely large and diverse chemical space in a matter of days and move through the optimization process quickly by focusing only on those compounds predicted to have improved target-binding attributes.

“As Charles River continues to expand its early drug discovery portfolio, innovative solutions, including Atomwise’s AI technology, enable us to provide clients with a comprehensive, integrated platform for their early-stage drug research. By cutting time out of each stage of the drug discovery process, we enable our clients to deliver novel therapeutics to patients more efficiently and effectively.” –James Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories

This alliance combines two industry-leading drug discovery platforms: Atomwise’s AI technology and Charles River’s unique portfolio of end-to-end drug discovery and early-stage development capabilities and expertise. Leveraging Atomwise’s AI technology and Charles River’s integrated drug discovery platform has the potential to significantly streamline the hit discovery, hit-to-lead, and lead optimization process for clients’ research efforts.

Through the collaboration, Charles River will have access to Atomwise’s AI technology to use with their existing portfolio of drug discovery services. Atomwise’s patented technology can analyze billions of compounds and screen challenging target proteins in the small molecule drug discovery process. The advantages of Atomwise’s AI technology will provide Charles River’s clients with the opportunity to efficiently screen billions, and evaluate thousands, of compounds to optimize potency, selectivity, and toxicity during hit and lead identification before committing resources to assays or syntheses.

As a result, Charles River’s clients can expect increased efficiency and diversity in the drug discovery process, ultimately reducing the expected timeline for an integrated drug discovery project and expanding the chemical space examined.

Furthering a Commitment to Flexible, Efficient Drug Discovery

The Atomwise AI technology platform will allow Charles River to enhance standard approaches to the identification and optimization of small molecules. This represents another progressive step for Charles River as the company has completed a series of technology partnerships that both elevate and expand the reach of its portfolio, providing Charles River’s clients with next-generation discovery platforms to accelerate programs into the clinic.

Related Articles Read More >

8 reasons all is not well in GenAI land
Efficiency first: Sandia’s new director balances AI drive with deterrent work
GreyB’s AI-driven Slate offers single search across 160 million patents, 264 million papers
Webinar offers guide to R&D data clarity with perspectives from a Big Pharma, global CRO, space‑station lab, and immune-system-in-a-dish startup
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE